Proteomics may unlock key clues to mepolizumab success in rare lung disease
NCT ID NCT07343661
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to understand disease progression and treatment effects. The goal is to improve personalized care and potentially use less invasive saliva tests instead of blood draws.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mepolizumab (Nucala)
- What this could lead to
- If successful, this could identify biomarkers to predict which patients will respond best to mepolizumab, improving personalized treatment for EGPA and severe asthma.
- What could go wrong
- This is an early-phase observational study focused on biomarkers, not a treatment trial. The findings may not lead to immediate clinical changes or benefit participants directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Policlinico Duilio Casula AOU Cagliari
Cagliari, Cagliari, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle